Header Logo

Connection

Michael Liptay to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Michael Liptay has written about Lung Neoplasms.
Michael Liptay
Connection Strength
8.292
Lung Neoplasms
  1. Improved False-Positive Rates and the Overestimation of Unintended Harm from Lung Cancer Screening. Lung. 2019 06; 197(3):327-332.
    View in: PubMed
    Score: 0.447
  2. 50th Anniversary Landmark Commentary on Jensik RJ, Faber LP, Kittle CF. Segmental resection for bronchogenic carcinoma. Ann Thorac Surg 1979;28:475-83. Ann Thorac Surg. 2015 Sep; 100(3):776-7.
    View in: PubMed
    Score: 0.348
  3. Smaller incisions for smaller cancers. Oncology (Williston Park). 2015 Mar; 29(3):166; 168.
    View in: PubMed
    Score: 0.336
  4. Status of sentinel lymph node mapping in non-small cell lung cancer. Cancer J. 2015 Jan-Feb; 21(1):17-20.
    View in: PubMed
    Score: 0.332
  5. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.242
  6. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol. 2009 Dec 15; 100(8):703-7.
    View in: PubMed
    Score: 0.234
  7. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.230
  8. Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg. 2010 Mar; 139(3):606-11.
    View in: PubMed
    Score: 0.229
  9. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.222
  10. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
    View in: PubMed
    Score: 0.220
  11. Sentinel node mapping in lung cancer: introduction. Semin Thorac Cardiovasc Surg. 2009; 21(4):297.
    View in: PubMed
    Score: 0.219
  12. Cytologic imprints of giant atypical bronchopulmonary carcinoid tumor of the lung with extensive oncocytic component. Diagn Cytopathol. 2008 Dec; 36(12):887-90.
    View in: PubMed
    Score: 0.218
  13. Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 2008 Oct; 144(4):712-7; discussion 717-8.
    View in: PubMed
    Score: 0.214
  14. Sentinel node mapping in lung cancer: the Holy Grail? Ann Thorac Surg. 2008 Feb; 85(2):S778-9.
    View in: PubMed
    Score: 0.206
  15. Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008 Jan; 33(1):89-94.
    View in: PubMed
    Score: 0.202
  16. Metastatic breast cancer and lung cancer within the same lymph node. Int J Surg Pathol. 2007 Apr; 15(2):169.
    View in: PubMed
    Score: 0.194
  17. In vivo sentinel lymph node mapping in lung cancer. Ann Surg Oncol. 2005 Feb; 12(2):102-3.
    View in: PubMed
    Score: 0.167
  18. Sentinel lymph node mapping in lung cancer. Cancer Treat Res. 2005; 127:141-50.
    View in: PubMed
    Score: 0.166
  19. Sentinel node mapping in lung cancer. Ann Surg Oncol. 2004 Mar; 11(3 Suppl):271S-4S.
    View in: PubMed
    Score: 0.157
  20. Current concepts in the staging of non-small cell lung cancer. Surg Oncol. 2002 Dec; 11(4):181-90.
    View in: PubMed
    Score: 0.144
  21. Commentary on sentinel lymph node identification with technetium-99m tin colloid in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002 Sep; 124(3):428-30.
    View in: PubMed
    Score: 0.141
  22. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 2002 Apr 15; 20(8):1984-8.
    View in: PubMed
    Score: 0.138
  23. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
    View in: PubMed
    Score: 0.136
  24. Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. J Thorac Cardiovasc Surg. 2021 12; 162(6):1605-1618.e6.
    View in: PubMed
    Score: 0.131
  25. Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry. Lung. 2021 06; 199(3):311-318.
    View in: PubMed
    Score: 0.129
  26. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg. 2000 Aug; 70(2):384-9; discussion 389-90.
    View in: PubMed
    Score: 0.122
  27. A Prolonged Air Leak Score for Lung Cancer Resection: An Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database. Ann Thorac Surg. 2019 11; 108(5):1478-1483.
    View in: PubMed
    Score: 0.114
  28. Complications from induction regimens for thoracic malignancies. Perioperative considerations. Chest Surg Clin N Am. 1999 Feb; 9(1):79-95.
    View in: PubMed
    Score: 0.110
  29. Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol. 2018 Jul; 79(7):558-563.
    View in: PubMed
    Score: 0.104
  30. Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98.
    View in: PubMed
    Score: 0.103
  31. Reply. Ann Thorac Surg. 2018 07; 106(1):316-317.
    View in: PubMed
    Score: 0.102
  32. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
    View in: PubMed
    Score: 0.100
  33. Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. Lung. 2016 08; 194(4):619-24.
    View in: PubMed
    Score: 0.091
  34. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
    View in: PubMed
    Score: 0.091
  35. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.087
  36. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015 Aug; 100(2):429-36.
    View in: PubMed
    Score: 0.086
  37. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
    View in: PubMed
    Score: 0.084
  38. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
    View in: PubMed
    Score: 0.084
  39. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.082
  40. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
    View in: PubMed
    Score: 0.081
  41. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
    View in: PubMed
    Score: 0.079
  42. Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
    View in: PubMed
    Score: 0.079
  43. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
    View in: PubMed
    Score: 0.072
  44. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.072
  45. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.072
  46. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
    View in: PubMed
    Score: 0.071
  47. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.066
  48. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.065
  49. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.065
  50. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.062
  51. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.062
  52. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.062
  53. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg. 2010 Sep; 90(3):875-81; discussion 881-3.
    View in: PubMed
    Score: 0.061
  54. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
    View in: PubMed
    Score: 0.061
  55. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.060
  56. Cytologic features of adult spindle cell variant of rhabdomyosarcoma: a report of two cases. Diagn Cytopathol. 2009 Dec; 37(12):932-4.
    View in: PubMed
    Score: 0.058
  57. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2009 Sep; 88(3):945-50; discussion 950-1.
    View in: PubMed
    Score: 0.057
  58. Endobronchial colorectal metastasis versus primary lung cancer: a tale of two sleeve right upper lobectomies. Interact Cardiovasc Thorac Surg. 2009 Aug; 9(2):379-81.
    View in: PubMed
    Score: 0.056
  59. Contemporary review on the inequities in the management of lung cancer among the African-American population. J Natl Med Assoc. 2008 Jun; 100(6):683-8.
    View in: PubMed
    Score: 0.053
  60. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug; 45(2):243-53.
    View in: PubMed
    Score: 0.040
  61. Critical factors for patient management. Lung Cancer. 2003 Dec; 42 Suppl 1:S7-8.
    View in: PubMed
    Score: 0.039
  62. Solitary pulmonary nodule: treatment options. Chest. 1999 Dec; 116(6 Suppl):517S-518S.
    View in: PubMed
    Score: 0.029
  63. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997 Apr; 113(4):691-8; discussion 698-700.
    View in: PubMed
    Score: 0.024
  64. Small pulmonary lesions detected at CT: clinical importance. Radiology. 1997 Jan; 202(1):105-10.
    View in: PubMed
    Score: 0.024
  65. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg. 1996 Mar; 61(3):977-82.
    View in: PubMed
    Score: 0.023
  66. An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S17-32.
    View in: PubMed
    Score: 0.021
  67. Age is a strong risk factor for atrial fibrillation after pulmonary lobectomy. Am J Surg. 2010 Apr; 199(4):558-61.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.